Monitoring rFVIII prophylaxis dosing using global haemostasis assays-Reference-Cited by-同舟云学术

Monitoring rFVIII prophylaxis dosing using global haemostasis assays

Published:2013-03-19 Issue:3 Volume:19 Page:409-414
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

AL Hawaj M. A.¹,Martin E. J.¹,Venitz J.²,Barrett J. C.³,Kuhn J. G.³,Nolte M. E.³,Brophy D. F.

Affiliation:

1. Coagulation Advancement Laboratory; Department of Pharmacotherapy & Outcomes Science; Virginia Commonwealth University School of Pharmacy; Richmond; VA; USA

2. Department of Pharmaceutics; Virginia Commonwealth University School of Pharmacy; Richmond; VA; USA

3. Central Virginia Center for Coagulation Disorders; Richmond; VA; USA

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12110/fullpdf

Reference32 articles.

1. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia;Ahnström;Haemophilia,2004

2. A cell-based model of hemostasis;Hoffman;Thromb Haemost,2001

3. Prophylactic dosing of factor VIII and IX from a clinical pharmacokinetic perspective;Björkman;Haemophilia,2003

4. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia;Collins;Haemophilia,2011

5. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens;Collins;J Thromb Haemost,2009

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hemostasis Assessment in Neonates: Evaluation of Viscoelastic Properties of Blood Clots;Newborn;2024-03-26

2. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09

3. Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX‐FP): A case report;Clinical Case Reports;2023-06

4. Antithrombin-lowering in hemophilia: a closer look at fitusiran;Research and Practice in Thrombosis and Haemostasis;2023-05

5. In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype;Research and Practice in Thrombosis and Haemostasis;2023-02